San Diego—Last fall, brentuximab vedotin (BV) was approved as part of a combination for the first-line treatment of CD30-expressing peripheral T-cell lymphomas (PTCLs)—even before the full data from a registration trial were published or presented—via a new streamlined FDA approval process.
About one month after the approval was granted, the full data from the registration trial, called ECHELON-2, were presented at the 2018 annual meeting of the American Society of Hematology